Orchestra BioMed Holdings Inc. has announced the publication of clinical data in JACC: Advances, revealing the potential benefits of their AtrioVentricular Interval Modulation (AVIM) therapy for patients with hypertension and diastolic dysfunction. The data, derived from a retrospective, treatment-blinded analysis of the MODERATO II study, indicates that AVIM therapy significantly reduced systolic blood pressure in both office and ambulatory settings, while also improving echocardiographic markers of diastolic dysfunction. These findings underscore the therapy's promise in addressing components that contribute to heart failure with preserved ejection fraction (HFpEF). The results were previously presented in a late-breaking session at the 2025 Technology and Heart Failure Therapeutics Meeting and are now accessible in the journal. The AVIM therapy is currently under evaluation in the BACKBEAT global pivotal study, conducted in association with Medtronic, aiming to secure U.S. regulatory approval for pacemaker-indicated patients with uncontrolled hypertension.